Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 2
2001 1
2002 1
2003 3
2005 1
2008 2
2009 3
2010 3
2011 3
2012 5
2013 5
2014 8
2015 7
2016 7
2017 10
2018 10
2019 10
2020 18
2021 10
2022 9
2023 10
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Results by year

Filters applied: . Clear all
Page 1
MYH9 Associated nephropathy.
Furlano M, Arlandis R, Venegas MDP, Novelli S, Crespi J, Bullich G, Ayasreh N, Remacha Á, Ruiz P, Lorente L, Ballarín J, Matamala A, Ars E, Torra R. Furlano M, et al. Among authors: novelli s. Nefrologia (Engl Ed). 2019 Mar-Apr;39(2):133-140. doi: 10.1016/j.nefro.2018.08.008. Epub 2018 Nov 22. Nefrologia (Engl Ed). 2019. PMID: 30471777 Free article. Review. English, Spanish.
Combination of G-CSF and a TLR4 inhibitor reduce inflammation and promote regeneration in a mouse model of ACLF.
Engelmann C, Habtesion A, Hassan M, Kerbert AJ, Hammerich L, Novelli S, Fidaleo M, Philips A, Davies N, Ferreira-Gonzalez S, Forbes SJ, Berg T, Andreola F, Jalan R. Engelmann C, et al. Among authors: novelli s. J Hepatol. 2022 Nov;77(5):1325-1338. doi: 10.1016/j.jhep.2022.07.006. Epub 2022 Jul 16. J Hepatol. 2022. PMID: 35843375 Free article.
Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure.
Engelmann C, Sheikh M, Sharma S, Kondo T, Loeffler-Wirth H, Zheng YB, Novelli S, Hall A, Kerbert AJC, Macnaughtan J, Mookerjee R, Habtesion A, Davies N, Ali T, Gupta S, Andreola F, Jalan R. Engelmann C, et al. Among authors: novelli s. J Hepatol. 2020 Jul;73(1):102-112. doi: 10.1016/j.jhep.2020.01.011. Epub 2020 Jan 24. J Hepatol. 2020. PMID: 31987990
Diagnostic imaging in COVID-19 pneumonia: a literature review.
Campagnano S, Angelini F, Fonsi GB, Novelli S, Drudi FM. Campagnano S, et al. Among authors: novelli s. J Ultrasound. 2021 Dec;24(4):383-395. doi: 10.1007/s40477-021-00559-x. Epub 2021 Feb 15. J Ultrasound. 2021. PMID: 33590456 Free PMC article. Review.
Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma.
Kim TM, Taszner M, Novelli S, Cho SG, Villasboas JC, Merli M, Jiménez-Ubieto A, Tessoulin B, Poon LM, Tucker D, Walewski J, Yi S, Song Y, Chong G, Bachy E, Guidez S, Alonso A, Jagadeesh D, Zhang W, Magnano L, Iskierka-Jażdżewska E, Tani M, Shen B, Uppala A, Zhu M, Shariff S, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Luminari S; ELM-2 Investigators. Kim TM, et al. Among authors: novelli s. Ann Oncol. 2024 Aug 13:S0923-7534(24)03759-1. doi: 10.1016/j.annonc.2024.08.2239. Online ahead of print. Ann Oncol. 2024. PMID: 39147364 Free article.
New therapies in non-Hodgkin lymphoma.
Novelli S, Sierra J, Briones J. Novelli S, et al. Expert Rev Anticancer Ther. 2015 Mar;15(3):349-59. doi: 10.1586/14737140.2015.1002773. Epub 2015 Jan 12. Expert Rev Anticancer Ther. 2015. PMID: 25582186 Review.
Excellent response to anti-CD38 therapy with daratumumab in a patient with severe refractory CANOMAD.
Pascual-Goñi E, Collet R, Tejada-Illa C, Martín-Aguilar L, Caballero-Ávila M, Lleixà C, Novelli S, López-Pardo J, Sanfeliu AE, Mariscal A, Álvaro Gargallo Y, Martínez-Hernández E, Cocho D, Querol L. Pascual-Goñi E, et al. Among authors: novelli s. J Neurol Neurosurg Psychiatry. 2024 Jun 17;95(7):609-611. doi: 10.1136/jnnp-2023-332443. J Neurol Neurosurg Psychiatry. 2024. PMID: 38341197
122 results